Tag: gene therapy on neurological diseases market analysis

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Gene Therapy On Neurological Diseases Market CAGR Outlook And Future Development

The gene therapy on neurological diseases market size has experienced swift expansion in recent years. It is projected to increase from $3.55 billion in 2025 to $4.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. The market’s past growth can be attributed to elements such as the scarcity of gene therapy alternatives for neurological conditions, the rising occurrence of Alzheimer’s and Parkinson’s disease, a dependence on traditional treatment methods, growing recognition of genetic methodologies, and the initial clinical testing of viral vectors.

The market size for gene therapy on neurological diseases is anticipated to experience substantial expansion in the coming years. It is projected to grow to $6.48 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This growth over the forecast period can be attributed to the advancement of adeno-associated virus and lentiviral therapies, the broadening of non-viral delivery platforms, a rise in regulatory approvals for neurological gene therapies, increased investment in research and development for targeted genetic interventions, and the incorporation of digital monitoring and AI-based patient management. Significant trends during the forecast period involve heightened investment in viral and non-viral gene therapy platforms, the expanding application of gene therapy across various neurological disorders, a growing emphasis on personalized and targeted genetic treatments, an increase in hospital and clinic-based gene therapy initiatives, and the creation of advanced delivery methods for neurological gene therapy.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=27294&type=smp&name=Gene%20Therapy%20On%20Neurological%20Diseases%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gene Therapy On Neurological Diseases Market Industry Drivers: What’s Behind The Revenue Growth?

The expanding occurrence of neurological conditions is projected to boost the gene therapy on neurological diseases market moving forward. These disorders are health conditions impacting the brain, spinal cord, and nerves, resulting in various symptoms like cognitive, motor, and sensory difficulties. Their rising frequency is associated with an aging demographic, given that aging progressively harms neuronal function, diminishes brain plasticity, and heightens oxidative stress, thus aiding in the onset and advancement of these conditions. Gene therapy on neurological diseases assists in managing neurological disorders by addressing their underlying genetic origins, providing potential enduring or permanent treatment options. This therapy enhances patient results through restoring or altering gene function, alleviating symptoms, and lessening the requirement for repeated medical procedures, consequently improving overall quality of life. For example, data from the National Health Service, a UK government body, indicated that by June 30, 2024, 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) in July 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the growing incidence of neurological disorders is fueling the expansion of the gene therapy on neurological diseases market.

Gene Therapy On Neurological Diseases Market Segment Landscape: Which Areas Lead Development?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

#Gene Therapy On Neurological Diseases Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the gene therapy on neurological diseases market are prioritizing the development of advanced viral delivery systems, such as the adeno-associated virus serotype 2 (AAV2) vector. Their aim is to enhance targeted gene delivery, increase efficacy, lessen immune reactions, and enable prolonged treatments. The adeno-associated virus serotype 2 (AAV2) vector is a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into specific cells, especially neurons, for sustained expression. As an illustration, in November 2024, PTC Therapeutics Inc., a biopharmaceutical company located in the US, obtained U.S. Food and Drug Administration (FDA) approval for a gene therapy designed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy utilizes an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, which facilitates dopamine production and improves motor functions. It is characterized by a single, intraputaminal infusion engineered to provide sustained therapeutic benefits, leading to significant improvements in motor function and a reduction in debilitating symptoms without the necessity for repeated interventions.

Gene Therapy On Neurological Diseases Market Industry Leaders And Competitive Landscape

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

View The Full Gene Therapy On Neurological Diseases Market Report:

https://thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gene Therapy On Neurological Diseases Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Gene Therapy On Neurological Diseases Market Growth Potential: How Will Market Size Change Through 2030?

The market for gene therapy targeting neurological disorders has seen swift expansion in recent years. Valued at $3.55 billion in 2025, it is projected to reach $4.01 billion by 2026, reflecting a compound annual growth rate (CAGR) of 13.0%. This historical growth has been driven by several factors, including the scarcity of available gene therapy options for neurological conditions, the rising incidence of Alzheimer’s and Parkinson’s diseases, a continued dependence on conventional treatment modalities, heightened awareness of genetic strategies, and the early-stage clinical testing of viral vectors.

The market for gene therapy targeting neurological diseases is projected to experience substantial expansion in the coming years. By 2030, its value is forecasted to reach $6.48 billion, reflecting a compound annual growth rate (CAGR) of 12.7%. This anticipated growth is driven by several factors, including the advancement of therapies based on adeno-associated viruses and lentiviruses, the broader development of non-viral delivery systems, an increase in regulatory approvals for neurological gene therapies, heightened investment in research and development focused on targeted genetic interventions, and the incorporation of digital monitoring tools along with AI-driven patient management approaches. Key trends shaping the forecast period involve growing financial commitments to both viral and non-viral gene therapy platforms, an expansion in the use of gene therapy for various neurological conditions, a heightened emphasis on personalized and precisely targeted genetic treatments, the proliferation of hospital and clinic-based gene therapy initiatives, and the creation of innovative delivery methods to advance neurological gene therapy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gene Therapy On Neurological Diseases Market Opportunity Drivers: What Is Creating New Revenue Potential?

The rising incidence of neurological disorders is anticipated to accelerate the expansion of the gene therapy market for neurological diseases in the foreseeable future. Neurological disorders encompass medical conditions that impact the brain, spinal cord, and nerves, resulting in various symptoms such as cognitive, motor, and sensory deficits. This uptick in neurological disorder cases is attributed to an aging population, where aging progressively diminishes neuronal function, reduces brain plasticity, and heightens oxidative stress, thereby facilitating the onset and advancement of these conditions. Gene therapy for neurological diseases supports the management of such disorders by addressing fundamental genetic causes, providing potentially lasting or permanent therapeutic options. It enhances patient outcomes by correcting or adjusting gene activity, alleviating symptoms, and decreasing the need for repeated treatments, thus improving overall life quality. For example, in July 2024, the National Health Service, a government organization in the UK, reported 487,432 patients diagnosed with dementia—a progressive brain disorder affecting memory, thinking, and daily activities—by June 30, 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the growing frequency of neurological disorders is fueling the progression of the gene therapy market for neurological diseases.

Gene Therapy On Neurological Diseases Market Segment Outlook: Which Categories Are Expanding The Fastest?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

Gene Therapy On Neurological Diseases Market Innovation Trends Driving Future Development

Major players in the gene therapy for neurological diseases market are concentrating on the development of sophisticated viral delivery platforms—like the adeno-associated virus serotype 2 (AAV2) vector—aimed at refining targeted gene transfer, boosting therapeutic effectiveness, lowering immune responses, and facilitating enduring treatments. Such a vector is described as a genetically engineered, non-harmful viral carrier employed in gene therapy to deliver therapeutic genes to specific cells, especially neurons, allowing sustained expression. As an example, in November 2024, PTC Therapeutics Inc., a biopharmaceutical firm based in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) for a gene therapy targeting aromatic L-amino acid decarboxylase (AADC) deficiency. This treatment leverages an AAV2 vector to transport a functional DDC gene copy into the putamen, thereby enabling dopamine synthesis and enhancing motor capabilities. It involves a single, intraputaminal infusion intended to deliver lasting therapeutic advantages, markedly improving motor function and alleviating severe symptoms while eliminating the requirement for repeated treatments.

Gene Therapy On Neurological Diseases Market Key Companies And Competitive Benchmarking

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Gene Therapy On Neurological Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gene Therapy On Neurological Diseases Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Gene Therapy On Neurological Diseases Market In 2026 And How Much Will It Reach By 2030?

The gene therapy on neurological diseases market size has experienced rapid expansion in recent years. It is projected to increase from $3.55 billion in 2025 to $4.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. The historical growth can be attributed to factors including the limited gene therapy options available for neurological diseases, the rising prevalence of Alzheimer’s and Parkinson’s disease, the reliance on conventional treatment methods, increasing awareness of genetic approaches, and early clinical trials of viral vectors.

The market for gene therapy targeting neurological diseases is projected to experience substantial expansion over the upcoming years. It is anticipated to reach $6.48 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This growth during the forecast period can be primarily attributed to factors such as advancements in adeno-associated virus and lentiviral therapies, the broadening of non-viral delivery platforms, an increase in regulatory approvals for neurological gene treatments, escalating investments in research and development for precise genetic interventions, and the incorporation of digital monitoring along with AI-driven patient management systems. Key trends expected during the forecast timeframe encompass increased funding for both viral and non-viral gene therapy platforms, the broadening of gene therapy applications to cover a wider range of neurological disorders, a heightened emphasis on individualized and targeted genetic therapies, the expansion of gene therapy initiatives within hospitals and clinics, and the innovation of sophisticated delivery techniques for neurological gene therapy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

What Important Drivers Are Powering The Gene Therapy On Neurological Diseases Market Growth?

The expanding occurrence of neurological disorders is anticipated to stimulate the growth of the gene therapy on neurological diseases market. These conditions are medical issues impacting the brain, spinal cord, and nerves, resulting in various cognitive, motor, and sensory difficulties. The rising incidence is connected to an aging demographic, as aging progressively impairs neuronal function, diminishes brain plasticity, and elevates oxidative stress, all contributing to the onset and progression of these ailments. Gene therapy on neurological diseases assists in managing these disorders by targeting their underlying genetic origins, providing potential lasting or permanent treatment options. It enhances patient results through restoring or altering gene function, alleviating symptoms, and lessening the need for repeated medical procedures, thus improving the overall quality of life. For example, in July 2024, the National Health Service, a UK-based government agency, reported 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the increasing prevalence of neurological disorders is fueling the expansion of the gene therapy on neurological diseases market.

Which Segment Divisions Form The Structure Of The Gene Therapy On Neurological Diseases Market?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What Trends Are Influencing The Gene Therapy On Neurological Diseases Market Outlook?

Major companies operating in the gene therapy on neurological diseases market are focusing on developing advanced viral delivery systems, such as adeno-associated virus serotype 2 (AAV2) vector. This development aims to improve targeted gene delivery, enhance efficacy, reduce immune reactions, and enable long-lasting treatments. The adeno-associated virus serotype 2 (AAV2) vector itself is a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into target cells, particularly neurons, for long-term expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for a gene therapy designed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy utilizes an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, enabling dopamine production and improving motor functions. It features a one-time, intraputaminal infusion engineered to provide sustained therapeutic benefits, significantly enhancing motor function and reducing debilitating symptoms without the need for repeated interventions.

Which Firms Are Competing In The Gene Therapy On Neurological Diseases Market?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Gene Therapy On Neurological Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

Which Region Contributes The Most To The Gene Therapy On Neurological Diseases Market?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gene Therapy On Neurological Diseases Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company

Switchboard Market Report 2026

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2026

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Market Report 2026

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Gene Therapy On Neurological Diseases Market Between 2026 And 2030?

The market for gene therapy on neurological diseases has expanded significantly in recent years. This market is forecasted to increase from $3.55 billion in 2025 to $4.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. Historically, this expansion can be linked to several factors: limited gene therapy options for neurological diseases, the growing prevalence of alzheimer’s and parkinsons disease, a persistent reliance on conventional treatment methods, heightened awareness of genetic approaches, and initial clinical trials of viral vectors.

The gene therapy for neurological diseases market is poised for significant expansion in the coming years. It is projected to achieve a size of $6.48 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth during this period can be attributed to several factors, including the advancement of adeno-associated virus and lentiviral therapies, the increased adoption of non-viral delivery platforms, a surge in regulatory approvals for neurological gene treatments, greater investment in research and development for precise genetic interventions, and the integration of digital monitoring and AI-assisted patient management. Prominent developments in the forecast period encompass escalating investment in both viral and non-viral gene therapy platforms, the broadening application of gene therapies across neurological disorders, an intensified focus on personalized and targeted genetic treatments, the proliferation of hospital and clinic-based gene therapy programs, and the innovation of advanced delivery methods for neurological gene therapy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Which Key Factors Are Driving The Gene Therapy On Neurological Diseases Market Growth?

The increasing occurrence of neurological disorders is expected to drive the expansion of the gene therapy on neurological diseases market moving forward. Neurological disorders are health conditions that impact the brain, spinal cord, and nerves, leading to a variety of symptoms including cognitive, motor, and sensory impairments. The rising prevalence of neurological disorders is linked to the aging population, as aging gradually impairs neuronal function, reduces brain plasticity, and elevates oxidative stress, contributing to the development and progression of these conditions. Gene therapy for neurological diseases assists in managing these disorders by addressing their fundamental genetic causes, presenting potential long-term or permanent treatment solutions. It improves patient outcomes by restoring or modifying gene function, reducing symptoms, and minimizing the need for repetitive interventions, thereby enhancing overall quality of life. For instance, in July 2024, according to the National Health Service, a UK-based government agency, there were 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. Therefore, the growing incidence of neurological disorders is propelling the growth of the gene therapy on neurological diseases market.

Which Segment Classifications Are Used In The Gene Therapy On Neurological Diseases Market Segment Analysis?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What Trends Are Transforming The Gene Therapy On Neurological Diseases Market?

Firms operating within the gene therapy on neurological diseases market are concentrating on creating sophisticated viral delivery systems, specifically the adeno-associated virus serotype 2 (AAV2) vector, to enhance targeted gene delivery, boost effectiveness, minimize immune responses, and allow for prolonged therapeutic effects. The adeno-associated virus serotype 2 (AAV2) vector is defined as a modified, non-pathogenic viral carrier system employed in gene therapy to transport therapeutic genes into specific target cells, predominantly neurons, ensuring their sustained expression. As an illustration, in November 2024, PTC Therapeutics Inc., a biopharmaceutical firm based in the US, secured approval from the U.S. Food and Drug Administration (FDA) for its gene therapy designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This particular therapy utilizes an AAV2 vector to introduce a functional DDC gene copy into the putamen, thereby facilitating dopamine production and enhancing motor functions. Characterized by a single, intraputaminal infusion, it aims to deliver lasting therapeutic advantages, considerably boosting motor function and alleviating debilitating symptoms without requiring subsequent treatments.

Which Firms Are Contributing To The Gene Therapy On Neurological Diseases Market Ecosystem?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

Get The Full Gene Therapy On Neurological Diseases Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

Which Region Accounts For The Largest Portion Of The Gene Therapy On Neurological Diseases Market?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gene Therapy On Neurological Diseases Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company

Switchboard Market Report 2026

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2026

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Market Report 2026

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Gene Therapy On Neurological Diseases Market Over The Period 2026–2030?

The market for gene therapy on neurological diseases has expanded swiftly in recent years. It is anticipated to grow from $3.55 billion in 2025 to $4.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. The expansion observed in the past can be ascribed to several factors, including the restricted gene therapy options for neurological diseases, the rising prevalence of alzheimer’s and parkinsons disease, the prevailing dependence on conventional treatment methods, increased awareness of genetic approaches, and early clinical trials involving viral vectors.

The gene therapy on neurological diseases market is projected for significant expansion in the coming years, reaching $6.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This anticipated growth is driven by several factors, including advancements in adeno-associated virus and lentiviral treatments, the broadening of non-viral delivery methods, more regulatory approvals for neurological gene therapies, increased research and development funding for specific genetic interventions, and the incorporation of digital monitoring alongside AI-powered patient management systems. Key trends during this period are expected to encompass greater investment in both viral and non-viral gene therapy platforms, a wider application of gene therapy in various neurological conditions, an enhanced emphasis on customized and precise genetic treatments, the expansion of gene therapy initiatives within hospitals and clinics, and the innovation of sophisticated delivery techniques for neurological gene therapy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Which Economic Or Industry Drivers Are Impacting The Gene Therapy On Neurological Diseases Market?

The expanding occurrence of neurological disorders is anticipated to stimulate the development of the gene therapy on neurological diseases market. These conditions are medical ailments impacting the brain, spinal cord, and nerves, resulting in various symptoms such as cognitive, motor, and sensory deficits. The rise in neurological disorders is connected to the aging demographic, given that aging progressively hinders neuronal operation, diminishes brain adaptability, and heightens oxidative stress, thus fostering the onset and advancement of these conditions. Gene therapy for neurological diseases assists in managing these disorders by addressing their underlying genetic origins, thereby providing potential long-lasting or permanent therapeutic options. This approach enhances patient results through the restoration or alteration of gene function, alleviating symptoms, and decreasing the necessity for repeated procedures, consequently elevating the overall quality of life. An example illustrates this: in July 2024, figures from the National Health Service, a UK government body, indicated 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024. This represented an increase of 3,155 cases when compared to May 31, 2024. Consequently, the growing incidence of neurological disorders is fueling expansion in the gene therapy on neurological diseases market.

How Is The Gene Therapy On Neurological Diseases Market Divided Into Its Major Segments?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

How Are Trends Transforming The Gene Therapy On Neurological Diseases Market Landscape?

Leading companies within the gene therapy market for neurological diseases are concentrating on developing sophisticated viral delivery platforms, such as the adeno-associated virus serotype 2 (AAV2) vector. This focus aims to enhance targeted gene delivery, boost efficacy, minimize immune responses, and enable enduring treatments. The adeno-associated virus serotype 2 (AAV2) vector is recognized as a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into particular cells, especially neurons, for long-term gene expression. For example, in November 2024, PTC Therapeutics Inc., a biopharmaceutical firm based in the US, secured U.S. Food and Drug Administration (FDA) approval for its gene therapy intended for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This particular therapy utilizes an AAV2 vector to introduce a working copy of the DDC gene into the putamen, facilitating dopamine production and enhancing motor functions. It is administered as a single, intraputaminal infusion designed to deliver ongoing therapeutic advantages, markedly improving motor function and alleviating severe symptoms without requiring subsequent interventions.

Who Are The Prominent Organizations Shaping The Gene Therapy On Neurological Diseases Market?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

Read the full gene therapy on neurological diseases market report here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

What Are The Top-Performing Regions Within The Gene Therapy On Neurological Diseases Market?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gene Therapy On Neurological Diseases Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company

Switchboard Market Report 2026

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2026

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Market Report 2026

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy on neurological diseases market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Gene Therapy On Neurological Diseases Market in 2026, and what figure is it projected to hit by 2030?

The gene therapy on neurological diseases market size has experienced swift expansion in recent years. Projections show its value will climb from $3.55 billion in 2025 to $4.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. The market’s historical development can be ascribed to factors including limited gene therapy options for neurological diseases, the increasing prevalence of Alzheimer’s and Parkinson’s disease, an ongoing reliance on conventional treatment methods, a heightened awareness of genetic approaches, and the early clinical trials of viral vectors.

The gene therapy on neurological diseases market size is anticipated to experience substantial growth in the upcoming years, projected to reach $6.48 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.7%. This growth over the forecast period is driven by factors such as the development of adeno-associated virus and lentiviral therapies, the expansion of non-viral delivery platforms, an increase in regulatory approvals for neurological gene therapies, heightened investment in research and development for targeted genetic interventions, and the integration of digital monitoring and AI-based patient management. Prominent trends for the forecast period include a rise in investment across viral and non-viral gene therapy platforms, the broadening of gene therapy applications for various neurological disorders, an intensified focus on personalized and targeted genetic treatments, an expansion in hospital and clinic-based gene therapy programs, and the creation of advanced delivery methods for neurological gene therapy.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Which Drivers Are Affecting Market Participation In The Gene Therapy On Neurological Diseases Market?

The rising occurrence of neurological conditions is projected to boost the expansion of the gene therapy on neurological diseases market moving ahead. These disorders are health issues impacting the brain, spinal cord, and nerves, resulting in various symptoms like cognitive, motor, and sensory deficits. The growing incidence of neurological disorders is associated with an older demographic, given that aging progressively hinders neuronal activity, decreases brain adaptability, and heightens oxidative stress, thereby fostering the onset and advancement of such conditions. Gene therapy on neurological diseases assists in managing these disorders by addressing their underlying genetic origins, providing possible enduring or lasting treatment options. This therapy enhances patient results by restoring or altering gene function, alleviating symptoms, and lessening the need for repeated medical procedures, thus improving the overall quality of life. An example is provided by the National Health Service, a UK-based government agency, stating that in July 2024, 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, marking an increase of 3,155 cases from May 31, 2024. Consequently, the rising occurrence of neurological conditions is fueling the expansion of the gene therapy on neurological diseases market.

What Segment Classifications Make Up The Gene Therapy On Neurological Diseases Market?

The gene therapy on neurological diseases market covered in this report is segmented –

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What Industry Trends Are Transforming The Gene Therapy On Neurological Diseases Market?

Major companies operating in the gene therapy for neurological diseases market are prioritizing the development of advanced viral delivery systems, such as the adeno-associated virus serotype 2 (AAV2) vector, to enhance targeted gene delivery, improve efficacy, mitigate immune reactions, and enable long-lasting treatments. The Adeno-associated virus serotype 2 (AAV2) vector functions as a modified, non-pathogenic viral delivery system in gene therapy, designed to transport therapeutic genes into specific target cells, particularly neurons, for prolonged expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for a gene therapy intended for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy employs an AAV2 vector to deliver a functional DDC gene copy into the putamen, facilitating dopamine production and improving motor functions. It involves a single, intraputaminal infusion structured to deliver sustained therapeutic benefits, significantly enhancing motor function and reducing debilitating symptoms without the need for repeated interventions.

Which Leading Companies Dominate The Gene Therapy On Neurological Diseases Market Share?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

How Does The Gene Therapy On Neurological Diseases Market Perform Across Major Global Regions?

North America was the largest region in the gene therapy on neurological diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gene Therapy On Neurological Diseases Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2026, By The Business Research Company

Switchboard Market Report 2026

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2026

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Market Report 2026

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy on neurological diseases market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Growth Outlook For The Gene Therapy On Neurological Diseases Market?

The market size for gene therapy on neurological diseases has experienced significant growth in recent years. It is anticipated to expand from $3.13 billion in 2024 to $3.55 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.2%. This historical expansion can be attributed to several factors, including the increasing prevalence of neurological disorders, rising demand for personalized medicine, growing investment in biotech research and development, increasing clinical trial activities, and rising approvals for gene therapies.

The gene therapy on neurological diseases market size is anticipated to see considerable expansion in the upcoming years. This market is set to reach $5.76 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 12.9%. The projected growth for this period can be attributed to an increase in global clinical trial activity, ongoing development of healthcare infrastructure, rising awareness of rare diseases, an expanding pipeline of gene therapies, and a growth in partnerships and collaborations. Significant trends during the forecast period encompass the integration of technology in remote patient monitoring, innovations in vector manufacturing platforms, automation in biomanufacturing driven by technology, the development of gene therapies for ultra-rare pediatric central nervous system (CNS) disorders, and the incorporation of genomic screening into clinical settings.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

What Growth-Enabling Forces Are Impacting The Gene Therapy On Neurological Diseases Market?

The rising occurrence of neurological conditions is anticipated to fuel the expansion of the gene therapy on neurological diseases market in the foreseeable future. These conditions are health issues impacting the brain, spinal cord, and nerves, resulting in various symptoms such as cognitive, motor, and sensory difficulties. The growing incidence of neurological disorders is connected to an aging demographic, given that aging progressively hinders neuronal function, diminishes brain plasticity, and heightens oxidative stress, thereby facilitating the onset and advancement of these conditions. Gene therapy on neurological diseases assists in managing neurological disorders by addressing their underlying genetic causes, presenting prospects for enduring or permanent treatment options. This therapy enhances patient results through the restoration or modification of gene function, alleviating symptoms, and decreasing the necessity for repeated interventions, consequently improving the overall quality of life. For example, in July 2024, data from the National Health Service, a UK-based government agency, indicated that 487,432 patients had been diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, which marked an increase of 3,155 cases relative to May 31, 2024. Consequently, the rising prevalence of neurological disorders is stimulating the growth of the gene therapy on neurological diseases market.

How Does The Gene Therapy On Neurological Diseases Market Differ By Segment?

The gene therapy on neurological diseases market covered in this report is segmented

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What New Opportunities Are Emerging From Trends In The Gene Therapy On Neurological Diseases Market?

Leading companies in the gene therapy on neurological diseases market are prioritizing the development of advanced viral delivery systems, like the adeno-associated virus serotype 2 (AAV2) vector, to improve targeted gene delivery, increase efficacy, lessen immune reactions, and enable long-term treatments. The adeno-associated virus serotype 2 (AAV2) vector is a modified, non-pathogenic viral delivery system employed in gene therapy to transport therapeutic genes into target cells, particularly neurons, for prolonged expression. For instance, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for a gene therapy designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy utilizes an AAV2 vector to introduce a functional copy of the DDC gene into the putamen, thereby enabling dopamine production and enhancing motor functions. It features a single, intraputaminal infusion intended to deliver sustained therapeutic benefits, significantly improving motor function and reducing debilitating symptoms without requiring repeated interventions.

Who Are The Most Influential Companies In The Gene Therapy On Neurological Diseases Market?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

Which Region Is Leading Innovation In The Gene Therapy On Neurological Diseases Market?

North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2025, By The Business Research Company

Switchboard Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Surfing Boards Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Mobile Gaming Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mobile-gaming-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Gene Therapy On Neurological Diseases Market Between 2025 And 2029?

The gene therapy on neurological diseases market has seen substantial growth recently. It is anticipated to expand from $3.13 billion in 2024 to $3.55 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.2%. This historical growth can be ascribed to several factors, including the increasing occurrence of neurological disorders, a heightened demand for personalized medicine, rising investment in biotech research and development, an increase in clinical trial activities, and more approvals for gene therapies.

The gene therapy on neurological diseases market size is projected to experience swift expansion in the coming years. It is anticipated to reach $5.76 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.9%. The projected growth during this period is attributable to several factors, including heightened global clinical trial activity, advancements in healthcare infrastructure development, greater recognition of rare diseases, an expanding array of gene therapies in development, and a rise in strategic alliances and partnerships. Key trends foreseen for the forecast period encompass the incorporation of technology into remote patient monitoring, breakthroughs in vector manufacturing platforms, automation driven by technology in biomanufacturing processes, the creation of gene therapies specifically for ultra-rare pediatric central nervous system (CNS) disorders, and the assimilation of genomic screening within clinical environments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp

Which Drivers Are Impacting The Gene Therapy On Neurological Diseases Market?

The increasing incidence of neurological disorders is projected to drive the expansion of the gene therapy on neurological diseases market in the foreseeable future. Neurological disorders are medical conditions that impact the brain, spinal cord, and nerves, leading to a spectrum of symptoms including cognitive, motor, and sensory impairments. The rising prevalence of these conditions is connected to the aging population, as advancing age gradually impairs neuronal function, diminishes brain plasticity, and heightens oxidative stress, all contributing to their development and progression. Gene therapy on neurological diseases assists in managing these disorders by targeting their fundamental genetic causes, thereby offering potential long-term or permanent therapeutic solutions. This approach enhances patient outcomes by restoring or modifying gene function, alleviating symptoms, and minimizing the need for repetitive medical interventions, ultimately improving overall quality of life. For example, in July 2024, the National Health Service, a UK-based government agency, reported 487,432 patients diagnosed with dementia (a progressive brain disorder affecting memory, thinking, and daily activities) by June 30, 2024, reflecting an increase of 3,155 cases compared to May 31, 2024. Hence, the growing prevalence of neurological disorders is a significant factor propelling the growth of the gene therapy on neurological diseases market.

How Is The Gene Therapy On Neurological Diseases Market Classified Into Different Segments?

The gene therapy on neurological diseases market covered in this report is segmented

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)

What Are The Major Trends Driving The Growth Of The Gene Therapy On Neurological Diseases Market?

Key companies operating in the gene therapy on neurological diseases market are concentrating on developing advanced viral delivery systems, such as the adeno-associated virus serotype 2 (AAV2) vector. These systems aim to improve targeted gene delivery, enhance efficacy, mitigate immune reactions, and enable long-lasting treatments. The adeno-associated virus serotype 2 (AAV2) vector itself is a modified, non-pathogenic viral delivery system utilized in gene therapy to transport therapeutic genes into target cells, particularly neurons, for extended expression. For example, in November 2024, PTC Therapeutics Inc., a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for its gene therapy addressing aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy employs an AAV2 vector to deliver a functional copy of the DDC gene into the putamen, thereby enabling dopamine production and improving motor functions. The treatment involves a one-time, intraputaminal infusion, meticulously designed to offer sustained therapeutic benefits, substantially enhancing motor function and reducing debilitating symptoms without requiring repeated interventions.

Who Are The Core Companies Influencing The Gene Therapy On Neurological Diseases Market Landscape?

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report

What Are The Key Regional Factors Influencing The Gene Therapy On Neurological Diseases Market Growth?

North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gene Therapy On Neurological Diseases Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp

Browse Through More Reports Similar to the Global Gene Therapy On Neurological Diseases Market 2025, By The Business Research Company

Switchboard Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/switchboard-global-market-report

Mobile Computer Market 2025

https://www.thebusinessresearchcompany.com/report/mobile-computer-market

Surfing Boards Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/surfing-boards-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What CAGR Is Anticipated for the Gene Therapy On Neurological Diseases Market Through 2029?#_x000D_

The market for gene therapy in neurological conditions has witnessed significant expansion recently, and is projected to increase from $3.13 billion in 2024 to $3.55 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 13.2%. This development in the historical period is due to rising instances of neurological issues, a surge in interest for individualized medicinal treatments, escalated investment in biotechnological research and development, amplified clinical trial operations, and an increased number of authorizations for gene treatments._x000D_

_x000D_

The neurologic disease gene therapy market is anticipated to experience swift growth in the forthcoming years, swelling to a size of $5.76 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 12.9%. Numerous factors are contributing to this expected growth during the forecast period, including an upsurge in worldwide clinical trial activities, enhancements in healthcare infrastructure, increased awareness of uncommon diseases, an expanding gene therapy pipeline, and a rise in partnerships and collaborations. During the forecast period, several trends are projected to occur, such as the incorporation of technology into remote patient monitoring, innovating vector production platforms, the automation of biomanufacturing driven by technology, the development of gene therapies for extremely rare childhood Central Nervous System (CNS) diseases, and genomic screening integration in clinical environments._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=27294&type=smp_x000D_

_x000D_

#What Market Forces Are Driving The Gene Therapy On Neurological Diseases Sector In 2025 And Beyond?#_x000D_

The escalating incidence of neurological conditions is poised to spur the expansion of the market for gene therapy on neurological diseases. Neurological disorders encompass medical conditions that impact the brain, spinal cord, and nerves, resulting in a myriad of symptoms such as cognitive, motor, and sensory impairments. The upward trend in neurological disorders is intertwined with the growing aged population, as age-related neuronal function deterioration, decreased brain plasticity, and enhanced oxidative stress promote the onset and progression of these conditions. Gene therapy for neurological diseases delivers assistance in managing these disorders by targeting the underlying genetic triggers, thus providing potential long-lasting, or even permanent, treatment alternatives. This offers improved patient results by rectifying or modifying gene functionality, alleviating symptoms, and reducing the necessity for recurrent interventions, thereby promoting an improved overall quality of life. For instance, as reported by the National Health Service, a UK-based government agency, by June 30, 2024, there were 487,432 patients diagnosed with dementia (a degenerative brain disorder affecting memory, cognition, and daily activities), marking an increase of 3,155 cases as compared with May 31, 2024. Consequently, the escalating incidence of neurological disorders is fueling the growth of the gene therapy on neurological diseases market._x000D_

_x000D_

#How Is The Global Gene Therapy On Neurological Diseases Market Categorized By Segments?#_x000D_

The gene therapy on neurological diseases market covered in this report is segmented_x000D_

_x000D_

1) By Type: Viral Gene Therapy, Non-Viral Gene Therapy_x000D_

2) By Target Disease: Alzheimer’s Disease, Parkinsons Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis_x000D_

3) By Administration Route: Intravenous, Intrathecal, Intranasal, Intracerebral, Other Administration Routes_x000D_

4) By Application: Hospital, Clinic, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Viral Gene Therapy Type: Adeno Associated Virus, Lentivirus, Retrovirus, Herpes Simplex Virus, Adenovirus_x000D_

2) By Non-Viral Gene Therapy Type: Liposomes, Nanoparticles, Electroporation, Gene Gun, Naked Plasmid Deoxyribonucleic Acid (DNA)_x000D_

_x000D_

#What Long-Term Trends Are Likely To Affect The Gene Therapy On Neurological Diseases Market?#_x000D_

Leading companies in the gene therapy on neurological diseases market are focusing their efforts on creating state-of-the-art viral delivery systems, like adeno-associated virus serotype 2 (AAV2) vector. This is to enhance the precision of gene delivery, increase effectiveness, lower the likelihood of immune responses, and facilitate long-term treatments. The adeno-associated virus serotype 2 (AAV2) vector is essentially a modified, non-pathogenic viral delivery system used in gene therapy for delivering remedial genes into specific cells, primarily neurons, for prolonged expression. For example, PTC Therapeutics Inc., a biopharmaceutical firm based in the United States, obtained approval from the U.S. Food and Drug Administration (FDA) in November 2024 for gene therapy to treat aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy employs an AAV2 vector to transport a functional version of the DDC gene into the putamen, which enhances dopamine production and thereby enhances motor functions. This one-time, intraputaminal infusion aims to maintain therapeutic benefits, substantially improving motor function and reducing crippling symptoms without the requirement for continued interventions._x000D_

_x000D_

#Which Firms Are Considered Leaders In The Gene Therapy On Neurological Diseases Market Space?#_x000D_

Major companies operating in the gene therapy on neurological diseases market are Novartis AG, Biogen Inc., Neurocrine Biosciences Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Amicus Therapeutics Inc., Oxford Biomedica plc, Regenxbio Inc., Passage Bio Inc., Intellia Therapeutics Inc., Voyager Therapeutics Inc., UniQure N.V., AviadoBio Ltd., Capsida Biotherapeutics Inc., StrideBio Inc., Lysogene S.A., Wave Life Sciences Ltd., Taysha Gene Therapies Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG. _x000D_

_x000D_

#Get The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/gene-therapy-on-neurological-diseases-global-market-report_x000D_

_x000D_

#What Role Do Regional Policies And Investments Play In Gene Therapy On Neurological Diseases Market Expansion?#_x000D_

North America was the largest region in the gene therapy on neurological diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy on neurological diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=27294&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model